Stevenage, United Kingdom
NeRRe Therapeutics Ltd is a biotechnology startup based in the United Kingdom, founded in 2012. The company is focused on developing a breakthrough treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF). Their flagship product is orvepitant, a neurokinin (NK)-1 receptor antagonist, aiming to address unmet medical needs in patients with refractory or unexplained cough.
The recent £20.00M Series B investment on 07 July 2021 attracted a notable group of investors including Advent Life Sciences, Forbion, OrbiMed, Columbus Venture Partners, Fountain Healthcare Partners, and the British Business Bank.
The chronic cough associated with IPF is a significant issue for patients, often refractory to medical therapy with no approved treatments available. As a rare and terminal lung disease, IPF has been designated an orphan disease in both Europe and the USA, indicating a high medical need and potential market opportunity. NeRRe Therapeutics is well-positioned to address this unmet need and make a meaningful impact in the healthcare industry.
